Nuvo Pharmaceuticals Inc. (MRVFF) Research

Nuvo Pharmaceuticals Inc., which operates globally under the trade name Miravo Healthcare, specializes in delivering both prescription and over-the-counter medical products. The company's diverse portfolio addresses key therapeutic areas, including pain management, allergy relief, neurological conditions, and dermatological concerns. Its operations are structured into three distinct business units: a Commercial division, a Production and Service division, and a Licensing and Royalty division. Among its significant offerings are Blexten, an antihistamine prescribed for the symptomatic treatment of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine episodes; and Suvexx/Treximet, another medication for migraine. Nuvo also provides NeoVisc, an injectable viscosupplement utilized in managing osteoarthritis, alongside treatments for head lice infestations such as Resultz, FullMarks, and LAUSBUB. For metabolic health, the company supplies Bezalip SR, aimed at patients with elevated cholesterol or triglyceride levels, and Proferrin, an iron supplement for the prevention and treatment of iron deficiency. Their pain relief options include Fiorinal 1 and Fiorinal C1 for tension-type headaches, and Collatamp G, designed for surgical implantation during operations. Nuvo's gastrointestinal product line features PegaLAX, a laxative for occasional constipation; Mutaflor, a probiotic to manage chronic constipation, abdominal pain, and cramps; and MoviPrep, used for bowel cleansing in preparation for colonoscopies. Soriatane is available for the treatment of psoriasis and other keratinization disorders. Additionally, their range of topical solutions includes Pennsaid and Pennsaid 2% for osteoarthritic pain; Vimovo, which alleviates arthritis symptoms; SYNERA and RAPYDAN topical patches, employed to mitigate pain during needle sticks and other superficial skin procedures; and the Heated Lidocaine/Tetracaine Patch, applied prior to painful medical interventions. Yosprala is also part of their portfolio, focused on preventing heart attacks and strokes. The company was originally incorporated in 1983 and was formerly known as Nuvo Research Inc. It officially adopted the name Nuvo Pharmaceuticals Inc. in March 2016 and maintains its corporate headquarters in Mississauga, Canada.

Open Nuvo Pharmaceuticals Inc. (MRVFF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.